1.3 USD
-0.09 (-6.47%)
1.3393 USD
+0.04 (+3.02%)
ATNM gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 528 industry peers in the Biotechnology industry. The financial health of ATNM is average, but there are quite some concerns on its profitability. ATNM has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year ATNM has reported negative net income.
ATNM had a negative operating cash flow in the past year.
ATNM had negative earnings in each of the past 5 years.
ATNM had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
With a Return On Assets value of -65.12%, ATNM is not doing good in the industry: 60.61% of the companies in the same industry are doing better.
ATNM has a Return On Equity of -215.83%. This is in the lower half of the industry: ATNM underperforms 69.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -65.12% | ||
| ROE | -215.83% | ||
| ROIC | N/A |
ROA(3y)-46.19%
ROA(5y)-40.57%
ROE(3y)-100.2%
ROE(5y)-74.1%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ATNM so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ATNM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ATNM has been increased compared to 1 year ago.
The number of shares outstanding for ATNM has been increased compared to 5 years ago.
ATNM has a better debt/assets ratio than last year.
2.2 Solvency
ATNM has an Altman-Z score of -9.62. This is a bad value and indicates that ATNM is not financially healthy and even has some risk of bankruptcy.
ATNM has a worse Altman-Z score (-9.62) than 71.59% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that ATNM is not too dependend on debt financing.
The Debt to Equity ratio of ATNM (0.00) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.62 |
ROIC/WACCN/A
WACC8.82%
2.3 Liquidity
ATNM has a Current Ratio of 7.34. This indicates that ATNM is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 7.34, ATNM is doing good in the industry, outperforming 71.78% of the companies in the same industry.
ATNM has a Quick Ratio of 7.34. This indicates that ATNM is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 7.34, ATNM is doing good in the industry, outperforming 71.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.34 | ||
| Quick Ratio | 7.34 |
3. Growth
3.1 Past
ATNM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.43%, which is quite impressive.
ATNM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)21.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.76%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 14.82% on average over the next years. This is quite good.
The Revenue is expected to grow by 265.08% on average over the next years. This is a very strong growth
EPS Next Y13.26%
EPS Next 2Y16.17%
EPS Next 3Y13.56%
EPS Next 5Y14.82%
Revenue Next Year-76.23%
Revenue Next 2Y-41.42%
Revenue Next 3Y526.75%
Revenue Next 5Y265.08%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
ATNM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATNM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ATNM's earnings are expected to grow with 13.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.17%
EPS Next 3Y13.56%
5. Dividend
5.1 Amount
No dividends for ATNM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NYSEARCA:ATNM (1/12/2026, 8:04:00 PM)
After market: 1.3393 +0.04 (+3.02%)1.3
-0.09 (-6.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners19.79%
Inst Owner Change0%
Ins Owners2.36%
Ins Owner Change-1.12%
Market Cap40.56M
Revenue(TTM)N/A
Net Income(TTM)-41.04M
Analysts81.82
Price Target5.1 (292.31%)
Short Float %2.92%
Short Ratio3.8
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-20.9%
Min EPS beat(2)-80.18%
Max EPS beat(2)38.38%
EPS beat(4)2
Avg EPS beat(4)-1.2%
Min EPS beat(4)-80.18%
Max EPS beat(4)44.95%
EPS beat(8)6
Avg EPS beat(8)11.58%
EPS beat(12)7
Avg EPS beat(12)2.81%
EPS beat(16)8
Avg EPS beat(16)-7.72%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)11.42%
EPS NY rev (1m)0%
EPS NY rev (3m)19.1%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.13 | ||
| P/tB | 2.13 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.1
EYN/A
EPS(NY)-0.83
Fwd EYN/A
FCF(TTM)-0.98
FCFYN/A
OCF(TTM)-0.98
OCFYN/A
SpS0
BVpS0.61
TBVpS0.61
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -65.12% | ||
| ROE | -215.83% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-46.19%
ROA(5y)-40.57%
ROE(3y)-100.2%
ROE(5y)-74.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 0% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.34 | ||
| Quick Ratio | 7.34 | ||
| Altman-Z | -9.62 |
F-Score2
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)25.77%
Cap/Depr(5y)31.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.76%
EPS Next Y13.26%
EPS Next 2Y16.17%
EPS Next 3Y13.56%
EPS Next 5Y14.82%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-76.23%
Revenue Next 2Y-41.42%
Revenue Next 3Y526.75%
Revenue Next 5Y265.08%
EBIT growth 1Y5.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year21.87%
EBIT Next 3Y1.85%
EBIT Next 5Y-1.39%
FCF growth 1Y27.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.29%
OCF growth 3YN/A
OCF growth 5YN/A
ACTINIUM PHARMACEUTICALS INC / ATNM FAQ
What is the fundamental rating for ATNM stock?
ChartMill assigns a fundamental rating of 2 / 10 to ATNM.
Can you provide the valuation status for ACTINIUM PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 0 / 10 to ACTINIUM PHARMACEUTICALS INC (ATNM). This can be considered as Overvalued.
Can you provide the profitability details for ACTINIUM PHARMACEUTICALS INC?
ACTINIUM PHARMACEUTICALS INC (ATNM) has a profitability rating of 0 / 10.
Can you provide the financial health for ATNM stock?
The financial health rating of ACTINIUM PHARMACEUTICALS INC (ATNM) is 4 / 10.
What is the expected EPS growth for ACTINIUM PHARMACEUTICALS INC (ATNM) stock?
The Earnings per Share (EPS) of ACTINIUM PHARMACEUTICALS INC (ATNM) is expected to grow by 13.26% in the next year.